RT Journal Article
SR Electronic
T1 Retrospective Analyses of Interventions to Epidemics using a Continuously Updated Model, with Application to the COVID-19 Crisis in New York City
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.09.20228684
DO 10.1101/2020.11.09.20228684
A1 Osborn, Jenna
A1 Berman, Shayna
A1 Bender-Bier, Sara
A1 D’Souza, Gavin
A1 Myers, Matthew
YR 2020
UL http://medrxiv.org/content/early/2020/11/12/2020.11.09.20228684.abstract
AB Retrospective analyses of interventions to epidemics, in which the effectiveness of strategies implemented are compared to hypothetical alternatives, are valuable for performing the cost-benefit calculations necessary to optimize infection countermeasures. SIR (susceptible-infected-removed) models are useful in this regard but are limited by the challenge of deciding how and when to update the numerous parameters as the epidemic progresses. We present a method that uses a “dynamic spread function” to systematically capture the continuous variation in the population behavior throughout an epidemic. There is no need to update parameters as the effects of interventions are gradually manifested in the infection dynamics. We use the tool to quantify the reduction in infection rate realizable from the population of New York City adopting different facemask strategies during COVID-19. Assuming a baseline facemask of 67% filtration efficiency, calculations show that increasing the efficiency to 75% could reduced the roughly 5000 new infections per day occurring at the peak of the epidemic by about 40%. The turn-around time for the epidemic decreases from around 37 days to 31 days. Mitigation strategies that may not be varied as part of the retrospective analysis, such as social distancing, are automatically captured as part of the calibration of the dynamic spread function.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was internally funded by the FDA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB approval was requiredAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo human, animal, or in-vitro data is included in the manuscript, which describes a risk-assessment model. Algorithms used to derive the mathematical results have been referenced.